This review surveys #oncogenic #GeneFusions—particularly #TyrosineKinase fusions—examines detection methods, highlights targeted therapies, and underscores the importance of identifying fusion‑positive cancers. @gumedcenter.bsky.social
#OpenAccess #STTT: doi.org/10.1038/s413...
High-frequency gain-of-function PTK2/FAK splicing alternatives in SCLC are associated with elevated #TyrosineKinase activity, sensitivity to FAK inhibitors, and poor #Prognosis, highlighting their therapeutic potential.
#OpenAccess: doi.org/10.1038/s413...
RDAA, an #oncogenicdriver in non-mutated #NSCLC, demonstrates strong sensitivity to #FDA-approved #ALKinhibitors, highlighting a promising therapy option for patients lacking #TyrosineKinase mutations. @mdanderson.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
Screenshot of Graphical Abstract with heading that reads "INFANTILE MYOFIBROMATOSIS"
Novel germline intronic PDGFRB variant associated with infantile myofibromatosis is resistant to #targetedtherapy with imatinib bit.ly/3CpK32q #personalizedmedicine #tyrosinekinase
New @biorxivpreprint about our collaboration with the Gherardi group @unipv for #structuralbiology studies on MET receptor #tyrosinekinase and HGF mimic agonists #structuralbiology @DBB_UniPV x.com/biorxivpreprint/status/1...